Banking your baby’s cord blood is a long-term investment in your family’s health. Our management team understands this and governs itself accordingly in order to ensure that we will be there when and if you need us.

• The CBBC conducts its business in full compliance with the College of Physicians and Surgeons of Ontario's policies, and generally accepted good business practice.
• The CBBC conducts its business in accordance with The Canadian Medical Association’s (CMA) Ethical Practice Guidelines and consistent with generally accepted good business practice: the CBBC always has, is currently in the practice of, and will continue to refrain from entering into a coercive enrollment environment: refraining from signing and/or entering strategic/exclusive agreements with hospitals that limit the cord blood banking services available in any given hospital to only 1 provider.
• The Cord Blood Bank of Canada’s laboratory specializes in cord blood stem cell processing. All of our management and medical efforts are focused on our core business of cord blood stem cell banking. Although we support research efforts, we will not place our long-term stability and your baby’s cord blood stem cells at jeopardy with expensive and risky research and development ventures that may never see rewards. The cost estimate of bringing an entity to market has been estimated to be between $350 million¹ and $500 million².
  

1. Wierenga W. Strategic alliances and the changing drug discovery process. Pharmaceutical News. 1996;3(3):13-16.
2. Moore JM. The pharmaceutical industry: a background paper. National Health Policy Forum. Washington,DC: Pharmaceutical Research and Manufacturers of America. January 1996.